948 results about "Degenerative disease" patented technology

The invention discloses a retina thickness prediction method and system based on a multi-modal image, and the method and system achieve the effective estimation of the retina thickness under a low-cost condition through feature alignment and fusion modeling, and improve the basic screening and follow-up visit capability. According to the invention, through fusion of the multi-mode retina image data, the structure and function information of the optic nerve can be more comprehensively obtained, and the prediction accuracy of the thickness of the retina nerve fiber layer (RNFL) is improved. The OCT high-resolution hierarchical structure and the wide-view texture features of the eye fundus image are combined, so that anatomy and pathological states of optic nerves can be truly restored. The method can be used as an auxiliary method for early screening and early warning of optic neurodegenerative diseases such as glaucoma, and provides support for low-cost and high-efficiency primary screening and clinical auxiliary decision making.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating Parkinson's disease and a preparation method thereof. The traditional Chinese medicine preparation for treating Parkinson's disease comprises the following raw materials in parts by weight: 20-30 parts of bischofia polycarpa, 17-25 parts of eucommia ulmoides, 12-16 parts of artemisia sphaerocephala, 10-15 parts of lycopodium clavatum, 8-13 parts of elm leaves, 7-14 parts of pericarpium citri reticulatae, 5-10 parts of semen cuscutae and 2-7 parts of liquorice. In the formula, monarch, minister, assistant and guide are reasonably matched, the curative effect is exact, and the effects of regulating qi and blood, nourishing liver, warming kidney, activating blood and dissipating blood stasis are achieved. The compound can effectively improve core symptoms of Parkinson's disease and delay disease progression, is expected to be further developed into clinical drugs for treatment of Parkinson's disease, and provides an innovative scheme for traditional Chinese medicine treatment of neurodegenerative diseases.

The present disclosure, in part, provide compounds of Formula (I) that are VPS34 inhibitors, compositions, and methods of use thereof, such as in methods of treating cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections:

The invention relates to the technical field of nervous system dysfunction, in particular to a nerve regulation and control system for degenerative disease treatment based on multi-modal physiological feedback, which comprises a central processing unit, an optical radiation applicator, a mechanical vibration applicator, an integrated biological signal sensing array and a man-machine interaction module, cooperative stimulation is applied by using a multispectral light source and a broadband vibrator, and multi-dimensional physiological signals such as heart rate variability, myoelectricity, galvanic skin and the like are monitored in real time through a sensor array. A multi-parameter adaptive control algorithm built in the central processing unit can dynamically and intelligently adjust stimulation parameters based on the feedback signals to form an accurate personalized treatment closed loop. Meanwhile, the safety monitoring module based on the biological thermal model ensures the safety boundary of the treatment process. According to the invention, intelligent, self-adaptive and non-invasive treatment of nerve dysfunction is realized.

Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and / or regenerative responses. The disclosure also provides methods for treating or ameliorating disease, disorders and conditions associated with gp130 activity, particularly those associated with inflammatory and degenerative disorders, or combination thereof.

A method for identifying biomarkers indicative of neurodegeneration using a covariance neural network (VNN) includes providing a VNN trained on brain anatomical data primarily composed of healthy subjects, making the largest proportion of the population in the data. Brain anatomical data of a subject is provided as input, and, based on the input, the VNN generates a set of biomarkers and a brain health marker indicative of neurodegeneration of the subject.

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

The invention provides a novel light-sensitive channel protein VR2.0 and application thereof. The photosensitive channel protein VR2.0 series provided by the invention has an obvious treatment effect in treatment of retina photoreceptor cell degenerative diseases. The novel light-sensitive channel protein has higher light sensitivity, fast dynamics and low side effect; under the same light stimulation condition, the response frequency is fast, and stable current signals can be kept under high frequency response. The application provides a better choice for developing photogenetic therapy for retina photoreceptor cell degenerative diseases, and has important application and popularization values.

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.

The present invention relates to novel body tissue radiofrequency applicators (50), referred to as BTRFAs, as well as to a non-invasive medical head device useful for stabilizing and / or reversing the symptoms of neurodegenerative diseases and / or proteinopathies. The novel BTRFAs and medical head device are particularly useful for stabilizing and / or reversing the symptoms of Alzheimer's disease and / or Parkinson disease in a subject in need thereof.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic diastereoisomer and a preparation method and application thereof.The phenolic diastereoisomer has the chemical structural formula shown in the formula I and the formula II, the formula I is dextroisomer and is named as (+)-fresh bamboo juice phenol D, and the formula II is levoisomer and is named as (-)-fresh bamboo juice phenol D. A pair of phenolic diastereoisomer compounds (+)-fresh bamboo juice phenol D and (-)-fresh bamboo juice phenol D are successfully obtained from fresh bamboo juice, and an anti-neurotoxicity activity test shows that (+)-fresh bamboo juice phenol D has a remarkable protection effect on PC12 cell injury caused by glutamic acid and can be used for preparing medicines for preventing or treating neurodegenerative diseases; wide application prospects are realized.

The present application discloses different classes of mitochondrial uncoupling compounds having significantly improved pharmacokinetic properties and conventional mitochondrial uncoupling compounds, pharmaceutical compositions containing the compounds and / or prodrugs, and diseases that are useful in the treatment of diseases associated with mitochondrial dysfunction or benefits by modulation of mitochondrial activity. Methods of using the compounds, prodrugs, and pharmaceutical compositions in treatment of diseases, including diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), mitochondrial genetic diseases, neurodegenerative diseases, cancer, autoimmune diseases, and infectious diseases.

One aspect of the present disclosure is a composition for preventing or treating a retinal degenerative disease, capable of preventing or delaying retinal cell degeneration. The composition for preventing or treating a retinal degenerative disease, in one aspect, contains exosomes extracted from human-derived mesenchymal stem cells as an active ingredient.

The present application relates to a diacetylene compound represented by formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a use of the compound, the pharmaceutically acceptable salt thereof, and the pharmaceutical composition. The compound, or the pharmaceutically acceptable salt thereof and the pharmaceutical composition comprising same can be used for preparing a drug for treating or relieving neuroinflammation and neurodegenerative diseases.

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The present disclosure generally relates to novel chimeric antigen receptors (“CARs”), modified regulatory T cells (“Tregs”) expressing such CARs and / or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative / inflammatory activity, or which promote neuronal growth / survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and / or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.

The present invention relates to 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-ons and derivatives thereof, a method for producing the same, and a composition for prevention, improvement or treatment of neurodegenerative disease containing the same. Specifically, 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-ons and derivatives thereof, which are novel compounds of the present invention, can be used as an excellent composition for prevention, improvement or treatment of neurodegenerative disease.

The invention provides an application of two polycyclic polyisopentenyl acyl phloroglucinol compounds (PPAP) with different skeleton types in preparation of drugs for relieving / treating neurodegenerative diseases. Belongs to the technical field of medicines. Hypheronone A provided by the invention is a 1, 9-split-ring polycyclic polyisopentenyl phloroglucinol compound, and hypheronone L is a polycyclic polyisopentenyl phloroglucinol compound which is formed by carrying out intramolecular [4 + 2] cyclization on a monocyclic polyisopentenyl phloroglucinol compound and has a complex ring system. The compound hypherone A and the compound hypherone L both have the activity of enhancing the current of a voltage-gated T-type calcium channel, can be used for preparing medicines for treating neurodegenerative diseases, particularly can be used for preparing medicines for relieving and / or treating diseases such as spinal cerebellar ataxia, Alzheimer's disease and intellectual syndrome, and have clinical application value.

The present invention relates to an anti-apolipoprotein E4 (ApoE4) antibody and use thereof and, more specifically, to: an anti-ApoE4 antibody or an antigen-binding fragment thereof; a fusion in which the anti-ApoE4 antibody or an antigen-binding fragment thereof and one or more blood-brain barrier (BBB) receptor-binding peptides are bound; a method for preparing the fusion; and a composition for preventing or treating neurodegenerative diseases or metabolic diseases, comprising the anti-ApoE4 antibody or an antigen-binding fragment thereof, or the fusion.

The present invention relates to a method for determining the disc incision depth of posterior lumbar interbody fusion, comprising the following steps: (1) Selecting patients with lumbar degenerative diseases who have undergone X-ray examination and plain CT scan of lumbar intervertebral discs as samples; (2) Removing unqualified samples; (3) Taking anteroposterior and lateral X-rays of the lumbar spine with the patient standing, and performing tomographic scanning with the patient lying flat; (4) Measuring the lengths of the lower edges of the L3 (the third lumbar vertebra), L4 (the fourth lumbar vertebra), and L5 (the fifth lumbar vertebra) vertebral bodies in the X-ray films as the X-ray depths of the L3 / 4, L4 / 5, and L5 / S1 intervertebral spaces; (5) Performing statistical analysis using SPSS 18.0 software and making a table of the analysis results; (6) Obtaining the warning value of the disc incision depth based on the data results. This method provides the warning value of the insertion depth of the nucleus pulposus forceps for medical staff performing posterior lumbar interbody fusion, improving the safety and success rate of interbody fusion.

The invention relates to the technical field of natural medicines, and discloses huperzine A C12 site arylation series derivatives and a preparation method thereof, and application of the derivatives in preparation of medicines for treating central nervous system degenerative diseases. The derivative has a structure as shown in a general formula I. According to the preparation method, a natural product huperzine A is taken as a raw material, aryl bromide is taken as a substrate, one-step synthesis is carried out through palladium-catalyzed heck coupling reaction, and the compound has the advantages of high chemical selectivity, no need of functional group protection, rapidness and the like. In-vitro enzyme activity and cell experiments prove that the derivative not only shows potential acetylcholin esterase inhibitory activity, but also has high efficiency, low toxicity and better neuroprotective activity, and has a prospect in clinical treatment of Alzheimer's disease. The preparation of the derivatives also provides a design thought for the development of novel central nervous system disease treatment drugs.

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

Devices and methods for treating joint degeneration (e.g., intervertebral disc degeneration) are provided. An example method may comprise: (1) advancing a tip of an introducer needle into a nucleus pulpous of an intervertebral disc; (2) with the tip of the introducer needle in the nucleus pulpous, maneuvering, out of the tip of the introducer needle, a tip of a flexible needle into a region of a cartilaginous endplate (CEP) of the intervertebral disc; and (3) delivering, from an aperture of the flexible needle, therapeutic to the region of the CEP.

Disclosed is a method for treating a disease or condition characterized by neurodegeneration by administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of hinokitiol, a hinokitiol derivative, and an iron-transporting tropolone.

The invention discloses nucleus pulposus cells as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the steps that exosomes are collected from immortalized spherical nucleus pulposus cells and used for culturing the nucleus pulposus cells, the cultured nucleus pulposus cells have higher multiplication capacity, and large-scale in-vitro amplification of the nucleus pulposus cells is achieved; meanwhile, the cultured nucleus pulposus cells have higher extracellular matrix secretion capacity. The cultured nucleus pulposus cells are used for treating the intervertebral disc degeneration disease, the clinical use requirement can be met, and an effective treatment scheme is provided for treating the intervertebral disc degeneration disease.

The purpose of the present invention is to provide a novel method for increasing the number of newly generated neurons in the adult brain, and to provide a polynucleotide, a vector, and a pharmaceutical composition for use in the method. The present invention provides: a polynucleotide characterized by including (A) the nucleic acid sequence of the Plagl2 gene, (B) an miR-shRNA (microRNA adapted short hairpin RNA) nucleic acid sequence for the Dyrk1a gene, and (C) a promoter sequence operatively connected to the nucleic acid sequences; a vector including the polynucleotide; and a pharmaceutical composition including the polynucleotide and the vector.

The invention relates to an isoindole thioimine compound, preparation thereof and application of the isoindole thioimine compound as a sigma-2 receptor inhibitor. Catechol and isobutene are subjected to a series of reactions under certain conditions to obtain a solid product; carrying out a series of reactions on o-xylene and chlorosulfonic acid under certain conditions to obtain an oily product; and reacting the solid product with the oily product under a certain condition to obtain the isoindole thioimine compound. Compared with the prior art, when the isoindole thioimine compound prepared by the invention is combined with a sigma-2 receptor and allosteric regulates a sigma-2 receptor compound, the combination of adjacent A beta oligomers and a receptor on synapse is unstable, so that the A beta oligomers are removed from the synapse, the activity of the sigma-2 receptor can be effectively inhibited, and the activity of the sigma-2 receptor can be inhibited. The compound can be further used for preparing new medicines for treating tumors and neurodegenerative diseases.

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;or a pharmaceutically acceptable salt thereof.